-
2023-506526-37-00
5
2021-03-17
Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
2022-502600-79-00
4
2021-03-16
Endometrial cancer
-
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
-
2023-507890-17-00
5
2021-02-22
Anemia associated with myeloproliferative neoplasm (MPN)-associated my
-
2024-512354-21-00
4
2021-02-22
Newly diagnosed multiple myeloma
-
2024-515988-55-00
4
2021-02-22
Newly diagnosed multiple myeloma
-
2022-503072-84-00
5
2021-02-13
stage IIIa cardiac AL amyloidosis
-
2022-503073-11-00
5
2021-02-13
Stage IIIb cardiac AL amyloidosis
-
2024-511929-60-00
4
2021-01-28
Waldenström’s Macroglobulinemia
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2023-504959-27-00
5
2020-12-09
Participants with Limited Stage-Small Cell Lung Cancer, who have recei
-
2022-502123-21-00
4
2020-12-08
Advanced Renal Cell Carcinoma
-
2023-506911-16-00
5
2020-12-04
ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
-
2022-501645-70-00
5
2020-11-25
Crohns Disease
-
2022-502611-10-00
5
2020-11-24
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2023-506515-18-00
5
2020-10-23
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-506467-34-00
5
2020-10-20
Relapsing Multiple Sclerosis (MS)
-
2023-506877-37-00
5
2020-09-28
Relapsed/Refractory Multiple Myeloma
-
2024-513422-38-00
5
2020-09-28
Newly diagnosed multiple myeloma
-
2022-501522-38-00
5
2020-09-04
Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; Multiple Myeloma
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI